

## Role of TSLP in Nasal Polyp Inflammation

Joo-Hee Kim,<sup>1</sup> Hyun Jung Jin,<sup>2</sup> Young-Hee Nam,<sup>2</sup> Hae-Sim Park<sup>2\*</sup>

<sup>1</sup>Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea

<sup>2</sup>Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine expressed in skin, gut, lungs, and thymus. TSLP signals via the TSLP receptor (TSLPR), a heterodimer of the IL-7 receptor  $\alpha$  chain and TSLPR chain. The TSLPR chain is closely related to the common receptor  $\gamma$  chain, which is expressed on a wide range of cell types in allergic inflammation. TSLP exerts a profound influence on the polarization of dendritic cells to drive T helper (Th) 2 cytokine production.<sup>1</sup> TSLP also promotes T-cell proliferation directly in response to T-cell receptor activation and Th2 cytokine production, and supports B-cell expansion and differentiation. TSLP further amplifies Th2 cytokine production by mast cells and natural killer T cells.<sup>2</sup> These properties confer a critical role on TSLP in driving Th2-mediated inflammation. Several studies have suggested an active role of TSLP in allergic diseases, including atopic dermatitis, asthma, and allergic rhinitis, because increased TSLP expression was noted in target tissues.<sup>3,4</sup> Additionally, increased TSLP expression is seen in inflammatory conditions in response to a wide variety of allergens and viral infections<sup>5-7</sup> and in eosinophilic esophagitis.<sup>8,9</sup> Regarding the role of TSLP in nasal polyps, one study suggested increased TSLP expression in nasal polyp tissue, but it did not demonstrate any relationship between TSLP and any major inflammatory parameter, such as eosinophilic infiltration.<sup>4</sup>

The study by Kimura et al.<sup>10</sup> in this issue of the AAIR clearly demonstrated increased *in vivo* expression of TSLP mRNA and protein in the epithelial and infiltrating cells of patients with nasal polyps regardless of their atopic status. Furthermore, they showed that the TSLP expression correlated closely with the degree of eosinophilic inflammation and local IgE level in nasal polyp tissue. These findings suggest a potential role of TSLP in the pathogenesis of chronic inflammation found in nasal polyps via regulating Th2 and eosinophilic inflammation. Moreover, the authors localized the source of TSLP within the nasal polyp tissue, and noted TSLP expression in inflammatory cells,

various structural cells, and epithelial cells. These levels correlated significantly with the number of eosinophils in nasal polyp tissue, indicating that TSLP derived primarily from epithelial cells has a role in regulating eosinophilic inflammation in nasal polyps, possibly by driving Th2 type inflammation, which up-regulates eosinophilic chemoattractants.

Several points should be clarified in future studies. First, increased TSLP expression was noted in both atopic and non-atopic groups. In the atopic group, allergen exposure could increase TSLP expression, as described in previous studies, because it was demonstrated that allergen exposure increased TSLP production from bronchial epithelial cells, which would enhance Th2-derived inflammation in asthmatic airways.<sup>11,12</sup> However, the mechanism of elevated TSLP expression in the nasal polyp tissue of the non-atopic group is not understood. Second, because the mast cell is a major inflammatory cell in nasal polyp tissue and TSLP can activate mast cells as well as eosinophils, further studies should investigate the roles of TSLP in the survival and recruitment of mast cells in nasal polyps.

Recent interesting findings suggest that respiratory viral infections and the recruitment of Th2 cytokine-producing cells amplify Th2 inflammation via the induction of TSLP.<sup>5</sup> The clinical features of aspirin-exacerbated respiratory disease (AERD) include a very high prevalence of chronic rhinosinusitis and nasal polyposis in which Th2 and eosinophilic inflammations are the major findings.<sup>13</sup> Compared with other types of nasal polyp, the increased activated status of eosinophils is a characteristic finding of chronic nasal polyp tissue in AERD patients.<sup>14</sup> In this

**Correspondence to:** Hae-Sim Park, MD, PhD, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, San-5 Woncheondong, Yeongtong-gu, Suwon 442-749, Korea.

Tel: +82-31-219-5196; Fax: +82-31-219-5154; E-mail: hspark@ajou.ac.kr

Received: April 16, 2011; Accepted: April 22, 2011

• There are no financial or other issues that might lead to conflict of interest.

study, the subjects were classified into two groups according to their atopic status. They did not enroll nasal polyps from AERD patients. Thus, the next strategy is to evaluate the role of TSLP in chronic eosinophilic inflammation of nasal polyp tissue in AERD patients compared with non-AERD patients.

Several studies suggest that AERD develops as a result of chronic viral infection,<sup>15-17</sup> and respiratory viral infections are the most frequent exacerbating factors in AERD patients.<sup>18</sup> Moreover, a recent study showed that two genetic polymorphisms of the Toll-like receptor, *TLR3*, at -299698G>T and 293391G>A, were associated with the AERD phenotype.<sup>19</sup> Further studies are needed to investigate the role of TSLP in the development and exacerbation of symptoms in AERD patients.

### ACKNOWLEDGMENTS

This study was supported by a grant from the Korea Science and Engineering Foundation (KOSEF) funded by the Korean government (MEST, 2009-0078646).

### REFERENCES

- Ziegler SF. The role of thymic stromal lymphopoietin (TSLP) in allergic disorders. *Curr Opin Immunol* 2010;22:795-9.
- Wu WH, Park CO, Oh SH, Kim HJ, Kwon YS, Bae BG, Noh JY, Lee KH. Thymic stromal lymphopoietin-activated invariant natural killer T cells trigger an innate allergic immune response in atopic dermatitis. *J Allergy Clin Immunol* 2010;126:290-9.
- Liu T, Li TL, Zhao F, Xie C, Liu AM, Chen X, Song C, Cheng L, Yang PC. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. *Am J Med Sci* 2011;341:40-7.
- Zhu DD, Zhu XW, Jiang XD, Dong Z. Thymic stromal lymphopoietin expression is increased in nasal epithelial cells of patients with mugwort pollen sensitive-seasonal allergic rhinitis. *Chin Med J (Engl)* 2009;122:2303-7.
- Harada M, Hirota T, Jodo AI, Doi S, Kameda M, Fujita K, Miyatake A, Enomoto T, Noguchi E, Yoshihara S, Ebisawa M, Saito H, Matsumoto K, Nakamura Y, Ziegler SF, Tamari M. Functional analysis of the thymic stromal lymphopoietin variants in human bronchial epithelial cells. *Am J Respir Cell Mol Biol* 2009;40:368-74.
- Kato A, Favoreto S Jr, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. *J Immunol* 2007;179:1080-7.
- Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. *Nat Med* 2009;15:410-6.
- Sherrill JD, Gao PS, Stucke EM, Blanchard C, Collins MH, Putnam PE, Franciosi JP, Kushner JP, Abonia JP, Assaad AH, Kovacic MB, Biagini Myers JM, Bochner BS, He H, Hershey GK, Martin LJ, Rothenberg ME. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. *J Allergy Clin Immunol* 2010;126:160-5.
- Rothenberg ME, Spergel JM, Sherrill JD, Annaiah K, Martin LJ, Cianferoni A, Gober L, Kim C, Glessner J, Frackelton E, Thomas K, Blanchard C, Liacouras C, Verma R, Aceves S, Collins MH, Brown-Whitehorn T, Putnam PE, Franciosi JP, Chivavacci RM, Grant SF, Abonia JP, Sleiman PM, Hakonarson H. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. *Nat Genet* 2010;42:289-91.
- Kimura S, Pawankar R, Mori S, Nonaka M, Masuno S, Yagi T, Okubo K. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. *Allergy Asthma Immunol Res* 2011;3:186-193.
- Li YL, Li HJ, Ji F, Zhang X, Wang R, Hao JQ, Bi WX, Dong L. Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells. *J Asthma* 2010;47:117-23.
- Nagata Y, Kamijuku H, Taniguchi M, Ziegler S, Seino K. Differential role of thymic stromal lymphopoietin in the induction of airway hyperreactivity and Th2 immune response in antigen-induced asthma with respect to natural killer T cell function. *Int Arch Allergy Immunol* 2007;144:305-14.
- Palikhe NS, Kim JH, Park HS. Update on recent advances in the management of aspirin exacerbated respiratory disease. *Yonsei Med J* 2009;50:744-50.
- Lee YM, Kim SS, Kim HA, Suh YJ, Lee SK, Nahm DH, Park HS. Eosinophil inflammation of nasal polyp tissue: relationships with matrix metalloproteinases, tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta1. *J Korean Med Sci* 2003;18:97-102.
- Szczeklik A. Aspirin-induced asthma as a viral disease. *Clin Allergy* 1988;18:15-20.
- Yoshida S, Sakamoto H, Yamawaki Y, Shoji T, Akahori K, Onuma K, Nakagawa H, Hasegawa H, Amayasu H. Effect of acyclovir on bronchoconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma. *J Allergy Clin Immunol* 1998;102:909-14.
- van Rijt LS, van Kessel CH, Boogaard I, Lambrecht BN. Respiratory viral infections and asthma pathogenesis: a critical role for dendritic cells? *J Clin Virol* 2005;34:161-9.
- Filipowicz E, Sanak M. Exacerbation of aspirin-induced asthma associated with RSV infection. *Przegl Lek* 2003;60:185-7.
- Palikhe NS, Kim SH, Kim JH, Losol P, Ye YM, Park HS. Role of Toll-like Receptor 3 Variants in Aspirin-Exacerbated Respiratory Disease. *Allergy Asthma Immunol Res* 2011;3:123-7.